Strong Pills Warning EU - IKEA

'An 18-year-old man has died in Jersey, after taking "strong" ecstasy tablets. Kyle Pringle was taken to the General Hospital, but died there just before 6:30am on Saturday. Police say "the evidence suggests" Kyle's death was caused by consuming IKEA branded tablets. Officers had put out a warning about the tablets over the weekend, claiming they are "stronger than expected".'

http://www.itv.com/news/channel/2017-06-19/eighteen-year-old-dies-after-taking-strong-ecstasy-in-jersey/

• Posted by johnboy
• June 21, 2017

Mix of 25C-NBOMe, 4-FA and MDMA sold as MDMA in Melbourne AUS

tl;dr NBOMe mixtures sold as MDMA are around, don’t snort unknown caps, use test-kits wisely, look after your mates, and get your lab student/worker friends to contact us so we don’t need to rely on labs in Barcelona to access high-quality drug testing in Australia!

On the weekend 15-16 January 2017, there was a spate of poisonings, hospitalisations and deaths that have been associated a batch of capsules that were reportedly sold as MDMA or Ecstasy. Punters at Revolver nightclub and other clubs on Melbourne’s Chapel Street were affected.

The contents of these caps appeared damp, more like a brown sugar consistency than crystals or powder.

We obtained anonymous reports from people who consumed these capsules. The reports describe very strong hallucinogenic symptoms and paranoia. While in most cases, the symptoms resolved without medical intervention, they were very unpleasant, with one person reporting that they ‘felt like they were going to die or never be the same again’.

Reagent test kit results were shared by Bernie Maitri: these reports showed the substance was unlikely to be MDMA-like, and could instead contain PM(M)A or 2C-T-X. However these results were inconclusive, so we arranged to send a sample of this drug to Barcelona, where Energy Control conducts an international testing service. Mireia Ventura conducted the tests with GC/MS and LC/MS. The testing confirmed that the contents of the capsules:

- 4-FA (main substance)
- a low amount of MDMA
- 25C-NBOMe

This mixture is consistent with the reports. 25C-NBOMe is highly potent with only microgram doses required to produce strong hallucinogenic effects. 4-FA is an amphetamine-type stimulant which has been described as having an effect somewhere between amphetamine and MDMA. It is concerning that a low amount of MDMA was detected in the mixture, as this may be an indication that the manufacturers were hoping to fool reagent test kits by including enough MDMA to produce a positive result.

PLEASE GO TO BLUELIGHT FOR THE REST OF THIS ARTICLE

http://bluelight.org/vb/content/252-25C-NBOMe-4-FA-and-MDMA-mixture

• Posted by johnboy
• February 3, 2017

HOW TO RATE REPORTS

***PLEASE NOTE***

When rating a report (thumbs up/thumbs down), you are rating the QUALITY OF THE REPORT - *NOT* THE PILL!!

Thanks!
PR Admin Team & Mods.

• Posted by ravenousblonde
• October 25, 2009

How to Check an Online Doctor or Pharmacy is Registered in the UK

Ordering a repeat prescription from the sofa at ten at night is an ordinary thing to do in Britain now. The same search that brings up a regulated service also brings up websites with no pharmacist behind them, and from the outside it's hard to tell them apart. Both have a tidy homepage and a basket, and both promise next day delivery.

What separates them is registration, and anyone can look it up. With Anytime Doctor, for example, a UK-registered doctor reviews each consultation and only approves treatment if it's suitable. A registered pharmacy then dispenses it, and the company behind the service is overseen by its own regulator. All of these registers are free to search, and it's worth spending a few minutes on them before you type any personal details into a form.

Start with the pharmacy register

Every pharmacy operating in Great Britain has to be registered with the General Pharmaceutical Council, and that includes the ones that only exist online. The regulator is clear on this: checking its register is the only way to be sure a pharmacy is operating legally. A genuine site shows its registration number, usually on the homepage or on the About us page, and the GPhC's own page on checking the registration of online health services explains where to type it in. The result should show the same business name and the same address as the website, and a number that returns nothing, or a different business, is the moment to close the tab.

The doctor behind the prescription

Any prescription medicine has to be signed off by a prescriber. With an online service, that's usually a GP working remotely, who reads the patient's answers instead of seeing them in person. Doctors practising in the UK are registered with the General Medical Council, and the GMC register can be searched by name or by reference number. A healthcare professional should be happy to give their full name and registration number if asked. A reputable service won't mind the question.

The service itself answers to a regulator as well. In England that is the Care Quality Commission, which inspects online primary care providers and publishes what it finds. Wales, Scotland and Northern Ireland each have their own body: Healthcare Inspectorate Wales, Healthcare Improvement Scotland and the RQIA.

What a proper consultation asks for

The consultation itself tells you a lot. A regulated service asks questions before it approves anything: what medicines someone already takes, whether they have any allergies and what their medical history looks like. The prescriber reads those answers and decides whether the treatment is suitable. If they say no, that's a sign the checks are doing their job. Anyone who's used the same treatment for years can find the questions a chore on every reorder. They're asked each time because things change, whether that's a new medicine after a hospital stay, a pregnancy or a diagnosis since the last order. The GPhC's advice to patients puts giving an honest health history on the same list as checking the register, because a prescriber can only decide on what the form actually says. It's also a good sign if a service asks whether it can share details with the patient's own GP. It shows the service is happy for another doctor to see what it has prescribed.

Warning signs that it's time to go elsewhere

A site that will post prescription-only treatment after nothing more than a card payment has skipped the step the law requires. So has one that names no prescriber anywhere, or that pushes a bulk discount before any health information has been given. The MHRA's FakeMeds campaign sends buyers in Great Britain back to the GPhC register for exactly this reason. Before you fill in the first question of any consultation, copy the registration number shown on the site and paste it into that register.

• Posted by pradmin
• September 25, 2026

How AI-Powered Documentation Is Transforming Substance Abuse EMR Software 2026

Substance use disorder (SUD) treatment involves a distinct set of documentation requirements. This is because clinicians may need to record ASAM level-of-care decisions, relapse indicators, session notes, and consent documentation subject to 42 CFR Part 2. A single intake can generate more paperwork than three general medicine visits combined.

That burden is exactly why AI-powered documentation in SUD EMR has moved from a "nice to have" to a core evaluation criterion when treatment centers select or upgrade their substance abuse EMR software in 2026.

How Substance Abuse Documentation Differs

Before looking at what AI changes, it's worth being specific about how SUD documentation differs from standard behavioral health charting because of these reasons:

Regulatory and Confidentiality Requirements

SUD treatment records are subject to 42 CFR Part 2 in addition to HIPAA requirements. As a result, documentation may require specific consent language and disclosure tracking that general EMR systems are not always designed to support.

ASAM Criteria and Level-of-Care

Level-of-care decisions are documented against the six ASAM dimensions to establish the clinical basis for placement. The rationale should make clear why outpatient, intensive outpatient, residential, or medically managed detoxification is the appropriate setting for the patient's needs.

High Frequency of Clinical Documentation

A client may receive several types of care in the same week, such as group therapy, individual counseling, case management, and medication support. Each service usually requires its own note, which can quickly add to the documentation workload — especially in MAT programs that involve buprenorphine or methadone medications.

Relapse Assessment & Longitudinal Monitoring

Beyond recording completed services, SUD documentation identifies relapse risks and changes over time. Recognizing early warning signs often depends on connecting clinical information distributed across several encounters and treatment notes.

Traditional EMR templates provide the necessary structure, but the narrative reasoning expected by payers and auditors still falls largely to the clinician — and this is where AI is having the most measurable impact.

AI-Enabled Documentation Mechanisms

The term "AI documentation" is often used broadly, so it is important to distinguish the capabilities currently available in substance abuse EMR software from more general marketing claims. These capabilities typically include:

Ambient Note Generation from Sessions

With appropriate consent, voice-to-note tools in EMR capture individual or group sessions and convert the conversation into a structured draft, often using SOAP or DAP formats. Rather than creating the note from scratch, the clinician reviews and signs the generated documentation.

In group sessions involving six to ten participants, some platforms can also assign individual contributions to the appropriate client charts.

ASAM-Aligned Treatment Plan Drafting

AI systems use intake assessments, prior notes, and screening tools such as the ASI, AUDIT, and DAST-10 to build a draft treatment plan aligned with the relevant ASAM dimensions and level of care. This gives clinicians a clear starting point — with the core clinical context already organized and ready to refine.

Compliance & Consent Flagging

42 CFR Part 2 records demand a stricter standard of confidentiality — so some EMRs assign AI a precise task: flagging documentation that touches on sensitive substance use history and could trigger added disclosure safeguards. Before that note gets finalized, the system pauses and prompts the clinician to verify the requisite consent is properly on file.

Longitudinal Pattern Detection

AI models trained on behavioral health data can identify patterns across a client's record that may not be apparent from individual notes. These include clusters of missed appointments before a relapse, shifts in mood-related language over time, and gaps in medication adherence.

Once identified, these patterns can be flagged for the care team, helping emerging concerns stand out without requiring repeated review of earlier documentation.

Automated Coding & Claims Support

AI-assisted coding maps documented behavioral health and MAT services to the appropriate CPT and HCPCS codes. This helps reduce claim denials caused by documentation and coding mismatches — an ongoing challenge in SUD billing as service codes and requirements change over time.

Evidence Supporting Documentation Efficiency

Recent research provides a clearer view of where AI-assisted documentation is producing measurable gains in clinical practice. The strongest benefits appear in reduced documentation burden and improved clinician capacity, although financial returns tend to develop more gradually.

Impact of AI Scribes

Research across five academic medical centers, covering 1,800 clinicians, found measurable reductions in documentation burden among those using AI scribes. For every eight hours of patient care, users spent 16 minutes on documentation and 13 fewer minutes working within the medical record.

The study also found that adopters could accommodate roughly one additional patient every two weeks. On its own, that increase may seem modest — across a busy clinical practice, however, those small gains can add up to meaningful capacity over time.

ROI Timeline & Adoption Lag

The financial impact is less immediate. A Black Book Research survey spanning more than 7,800 respondents across 554 hospitals and 629 large practices found that 31% of organizations had piloted or deployed AI documentation tools at meaningful scale in 2025. Yet only 8% of adopters reported a positive return on investment (ROI) within the first 12 months — most expect measurable returns closer to two to two-and-a-half years out.

Key Takeaway

The evidence, therefore, points to measurable efficiency gains from AI documentation, with clinicians often seeing time savings relatively quickly. However, broader organizational value depends largely on adoption, workflow integration, governance, and sustained use over time.

Traditional vs. AI-Assisted Documentation Workflow

AI-assisted workflows reduce manual effort across several documentation tasks while maintaining clinician oversight. Key differences from traditional workflows include:

Bottom Line

An AI-powered EMR for substance abuse treatment should be judged by how well it reduces documentation burden without weakening compliance or clinical detail. Key areas include 42 CFR Part 2 consent tracking, ASAM-aligned treatment planning, and the reliability of ambient documentation across different care settings — especially group sessions.

Vendor claims also need to be weighed against real workflow performance. Besides that, implementation timelines, revision rates, and ambiguous clinical language can reveal more than broad accuracy claims. The strongest platform is one that improves efficiency without reducing the substance of the record — a balance that matters more than the AI label itself.

• Posted by pradmin
• August 19, 2026